{"nctId":"NCT00728416","briefTitle":"Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)","startDateStruct":{"date":"2008-08"},"conditions":["Allergic Rhinitis"],"count":333,"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","interventionNames":["Drug: Mometasone furoate nasal spray (MFNS)"]},{"label":"Arm 2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching placebo nasal spray"]}],"interventions":[{"name":"Mometasone furoate nasal spray (MFNS)","otherNames":["MK-0887, Nasonex Nasal Spray"]},{"name":"Matching placebo nasal spray","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A subject must be 12 years of age or older, of either sex, and of any race.\n* A subject must have at least a 2-year history of SAR which exacerbates during the study season.\n* A subject must have a positive skin prick test response to an appropriate seasonal allergen at Visit 1.\n* A subject must be clinically symptomatic at the Screening and Baseline Visits.\n\nExclusion Criteria:\n\n* A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.\n* A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days prior to the Screening Visit.\n* A subject who has used any drug in an investigational protocol in the 30 days prior to the Screening Visit.\n* A subject who is participating in any other clinical study.\n* A subject who is part of the staff personnel directly involved with this study.\n* A subject who is a family member (parent, spouse, or sibling) of the investigational study staff.\n* A female subject who is breast-feeding, pregnant, or intends to become pregnant.\n* A subject previously randomized into this study.\n* A subject who has a family member (parent, spouse, or sibling) currently enrolled in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days","description":"Nasal congestion was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. PRIOR (the subject's status over the previous 12 hours \\[reflective\\]). Baseline is the average score from the 3 days prior to the first dose of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"0.55"},{"groupId":"OG001","value":"-0.40","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days","description":"Total nasal symptom score (TNSS) is a composite of 4 symptoms, each is scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total can range from 0 to 12. PRIOR (the subject's status over the previous 12 hours \\[reflective\\]). Baseline is the average score from the 3 days prior to the first dose of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.00","spread":"2.03"},{"groupId":"OG001","value":"-1.73","spread":"2.03"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":168},"commonTop":[]}}}